An open-label, multicenter study to evaluate the efficacy and tolerability of a 4 week therapy with the fixed dose combination of valsartan 160 mg plus HCTZ 25 mg in hypertensive patients not adequately responding to a 4 week therapy with the free combination of an angiotensin receptor blocker (candersartan 32 mg) plus HCTZ 25 mg.
Phase of Trial: Phase III
Latest Information Update: 07 Nov 2011
At a glance
- Drugs Candesartan cilexetil; Hydrochlorothiazide; Valsartan/hydrochlorothiazide
- Indications Essential hypertension
- Focus Therapeutic Use
- Acronyms CICERO
- Sponsors Novartis
- 07 Nov 2011 Additional trial location (Switzerland) identified as reported by ClinicalTrials.gov.
- 08 Jun 2011 New trial record